AAM and the Biosimilars Council Call on Congress to Increase Patient Access to Biosimilars
Short-term CR adds biosimilars to Part D, but discourages biosimilar adoption in Part B WASHINGTON, D.C. (February 6, 2018) – The Association for Accessible Medicines (AAM) and the Biosimilars Council issued the following statement on the biosimilars provisions in the short-term continuing resolution (CR) released last night: “Biosimilar medicines offer enormous potential to lower […]
New Report Indicates Revising CMS Policy on Biosimilars Could Save $11.4 Billion On Medicines Over 10 Years
WASHINGTON, DC (September 19, 2017) — Today, the Association for Accessible Medicines (AAM) and its Biosimilars Council released an analysis finding that if the Centers for Medicare & Medicaid Services (CMS) were to revise its current reimbursement policy for biosimilar medicines, the federal government could save $11.4 billion on medicines over the next 10 years. […]
Five Reasons Why It’s Time to Lead on Biosimilars
September is nearly upon us, and registration is open for the Association for Accessible Medicines (AAM) and its Biosimilars Council’s 2017 two-day conference – Leading on Biosimilars, taking place on September 12 & 13 in Washington, D.C. The conference will feature presentations from key industry leaders, U.S. Government agency officials, and academic experts regarding the […]
Recapping: The Future for Biosimilars
On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by the Biosimilars Council, more than 100 influencers from across the country braved a late blast of winter weather to discuss the potential impact on the biosimilars industry of the new administration, changing regulations and recent FDA […]
The Future of Biosimilars – An Atlantic Policy Briefing
What does the future hold for biosimilars? How will the new administration, changing regulations and the recent FDA draft naming guidelines impact the industry? On March 15th, The Atlantic hosts “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing,” an event underwritten by the Biosimilars Council, held at the Newseum in Washington, D.C. to discuss these topics and […]
